Pfizer Inc. (NYSE:PFE) Stock Holdings Lowered by Chesley Taft & Associates LLC

Chesley Taft & Associates LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 1.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 150,137 shares of the biopharmaceutical company’s stock after selling 2,303 shares during the period. Chesley Taft & Associates LLC’s holdings in Pfizer were worth $3,804,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PFE. Norges Bank bought a new position in shares of Pfizer in the fourth quarter worth $2,328,986,000. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Starboard Value LP bought a new position in Pfizer in the 4th quarter valued at about $407,730,000. Raymond James Financial Inc. acquired a new position in Pfizer during the 4th quarter valued at about $274,694,000. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.3%

Shares of NYSE PFE opened at $23.42 on Thursday. The business has a fifty day simple moving average of $23.02 and a 200-day simple moving average of $25.02. The company has a market cap of $133.15 billion, a price-to-earnings ratio of 16.61, a P/E/G ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the firm posted $0.82 earnings per share. The firm’s quarterly revenue was down 7.8% compared to the same quarter last year. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.34%. The ex-dividend date is Friday, May 9th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PFE shares. UBS Group increased their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Finally, Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.